Cipla's shares surged 9.8% after the USFDA classified its Goa facility inspection as Voluntary Action Indicated (VAI), allowing for critical drug launches, including the Abraxane generic. Over the past year, the stock has risen 28.26%, with a 23% increase this year, despite a recent 7% decline.
